Advancing MDS Care: Navigating Challenges and Exploring the Patient Experience
EP. 1: Advances in MDS Classification and Molecular Understanding
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.
EP. 2: Choosing MDS Therapies: Risk-Based Approaches
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss risk-based approaches to choosing MDS therapies.
EP. 3: Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts offer insights on the COMMANDS trial findings.
EP. 4: ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss the data gathered from the ASCERTAIN trial.
EP. 5: Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.
EP. 6: HMA Persistence and Effectiveness in Higher Risk MDS
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
EP. 7: Innovations and Future Directions in Higher Risk MDS Treatments
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
EP. 8: Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.
EP. 9: Oral vs. IV HMAs: Considerations and Patient Guidance
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss considerations and patient guidance for oral and IV HMAs.
EP. 10: Patient Feedback for MDS: Insights and Closing Remarks
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts offer their insights and closing remarks regarding patient feedback for MDS.
